In clinics across the country, survival odds for people with HIV associated lymphoma have climbed to about 83%. That number, once out of reach, now matches what doctors see in the broader population. The shift comes from years of coordinated research, not a single discovery. Still, the 83% figure comes with caveats: it does not apply to every lymphoma subtype or stage, and study designs vary.
Paul G. Rubinstein, MD, at the University of Illinois Chicago, does not mince words. “No one should be excluded from any clinical trial.” For years, people with HIV were locked out of cancer studies. Oncologists had to guess how new drugs would work for them. The AIDS Malignancy Consortium (AMC), funded by the National Cancer Institute, changed that. Its trials now cover the full range of HIV—from advanced cases to those under control. CancerNetwork points out that pivotal registration trials for CD19-directed CAR-T therapies left out HIV-positive patients, so the evidence gap persisted.
The AMC-112 trial (NCT05077527) is the first prospective study to evaluate CAR-T therapy in patients with well-controlled HIV infection and relapsed/refractory aggressive B-cell lymphoma.
Rubinstein says the main hurdle is numbers. No single hospital sees enough HIV and cancer patients to run meaningful trials. Only by joining forces can researchers collect solid data. The AMC-085 study (NCT01771107) tested brentuximab vedotin (Adcetris) with doxorubicin, vinblastine, and dacarbazine (AVD) in HIV associated Hodgkin lymphoma. These networks have started enrolling patients in trials for new drugs, closing the evidence gap. AMC-085 focuses on Hodgkin lymphoma. AMC-112 tests axicabtagene ciloleucel (Yescarta) in aggressive B-cell non-Hodgkin lymphoma. Each trial targets a different disease and uses its own treatment plan and endpoints.
Safety is always in the spotlight. How far HIV has progressed affects infection risk during treatment. Rubinstein insists that with proper protection, outcomes match those in people without HIV. He warns against cutting chemotherapy short out of fear. That approach can backfire. Recent data from the CIBMTR and AMC compared 35 HIV-positive and 135 HIV-negative patients who got CD19-directed CAR-T therapy between August 2017 and November 2024. Cytokine release syndrome of any grade showed up less often in HIV-positive patients (68.6%) than in HIV-negative ones (82.2%), with a P value of 0.04.
Modern HIV drugs have changed the game, but mixing antiretrovirals with chemotherapy still takes careful planning. Rubinstein stresses the need for constant teamwork among doctors to avoid risky drug interactions and get dosing right. The AMC and NCI have built protocols to handle these challenges, letting more patients safely try advanced therapies. Ongoing studies like AMC-112 are still tracking safety and feasibility for CAR-T in this group. Final results are pending.
Retrospective studies by the AMC and Stefan Barta's group have reported comparable efficacy of CAR-T therapy in HIV-positive and HIV-negative patients, but these findings await confirmation from randomized comparative trials.
The next big step is bringing people with HIV into trials for CAR T cell therapy and bispecific antibodies. The AMC is running studies to test these therapies in HIV associated lymphomas, aiming to prove they work and are safe. This ends the old pattern of exclusion. As reported earlier, early data is already challenging outdated assumptions about who can benefit.
Cooperative research has raised survival rates for people with HIV associated lymphoma and set a new bar for trial access. When networks commit to enrolling all eligible patients, the gap in outcomes shrinks and new treatments reach those who need them. The field now faces a choice: expand access or risk leaving vulnerable groups behind as new therapies roll out.
